Sham Mailankody, MBBS

Sham Mailankody, MBBS, looks to the future treatment landscape for early relapsed/refractory multiple myeloma and addresses ways to improve patient access to care.

A medical oncologist discusses the significance of recent data and CAR T-cell therapy approvals in early relapsed/refractory multiple myeloma.

An expert on multiple myeloma provides a comprehensive overview of adverse events associated with CAR T-cell therapy and highlights strategies to monitor and manage AEs effectively.

Sham Mailankody, MBBS, summarizes recent data from the KarMMa-3 trial investigating ide-cel in patients with early relapsed/refractory multiple myeloma.

A myeloma specialist reviews the latest efficacy outcomes from the CARTITUDE-4 trial evaluating cilta-cel in patients with relapsed/refractory multiple and discusses how the results are informing treatment decisions.

Sham Mailankody, MBBS, provides an overview of challenges associated with CAR T-cell therapy in relapsed/refractory multiple myeloma, including location and financial considerations.

A medical oncologist discusses the referral process for patients being considered for CAR T-cell therapy in early relapsed/refractory multiple myeloma, highlighting factors that inform treatment selection.

An expert on multiple myeloma outlines key considerations for selecting early-line treatments for high-risk patients with relapsed/refractory multiple myeloma.

Sham Mailankody, MBBS, presents the case of a 70-year-old man with early relapse multiple myeloma and outlines clinical practices for identifying patients with high risk.

The depth and durability of responses seen with these CAR T-cell therapies in refractory myeloma is unprecedented and raises again the question of the role of up-front autologous stem cell transplant in the era of immune therapies, including CAR T-cell therapies.